SignalChem, Merck to evaluate SLC-391 + Keytruda in phase II study of advanced NSCLC

NCI is on the cusp of releasing designs for its National Cancer Plan, an initiative that would guide the institute’s mission and portfolio for years to come and engage everyone in oncology to “end cancer as we know it,” said NCI Director Monica Bertagnolli.